Erythropoietin in cardiac disease: New features of an old drugRuifrok, W-P. T., de Boer, R. A., Westenbrink, B. D., van Veldhuisen, D. J. & van Gilst, W. H., 13-May-2008, In : European Journal of Pharmacology. 585, 2-3, p. 270-277 8 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Erythropoietin is a haematopoietic hormone with extensive non-haematopoietic effects. The discovery of an erythropoietin receptor outside the haematopoietic system has fuelled the research into the beneficial effects of erythropoietin for various conditions, predominantly in cardiovascular disease. Experimental evidence has revealed the cytoprotective and angiogenic properties of erythropoietin and it seems that the erythropoietin-erythropoietin receptor system provides a powerful backbone against acute and chronic myocardial ischemia, each gaining from the different properties of erythropoietin. Clinical trials in which erythropoietin was titrated to achieve certain haematocrit levels have generated equivocal results. It has been suggested that a (too) high haematocrit is undesirable in cardiovascular disease. We have shown that intermittent (low-dose) erythropoietin administration, that does not increase haematocrit substantially, suffices to activate the beneficial downstream pathways of erythropoietin. We postulate that intermittent administration or a lower than conventional dose of erythropoietin, not only aimed at increasing haemoglobin at high levels, will provide powerful cellular protection and will improve cardiac outcome, without the side effects of erythropoietin associated with increased haematocrit. (C) 2008 Elsevier B.V. All rights reserved.
|Number of pages||8|
|Journal||European Journal of Pharmacology|
|Publication status||Published - 13-May-2008|
- erythropoietin, ischemia-reperfusion injury, myocardial infarction, chronic heart failure, apoptosis, neovascularization, ENDOTHELIAL GROWTH-FACTOR, ISCHEMIA-REPERFUSION INJURY, CHRONIC KIDNEY-DISEASE, CHRONIC HEART-FAILURE, LEFT-VENTRICULAR DYSFUNCTION, CORONARY-ARTERY LIGATION, MYOCARDIAL-INFARCTION, ENDOGENOUS ERYTHROPOIETIN, DARBEPOETIN-ALPHA, PROGENITOR CELLS